Health Care & Life Sciences » Biotechnology | Pluristem Therapeutics Inc.

Pluristem Therapeutics Inc. | Income Statement

Fiscal year is July-June. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
679.00
379.00
379.00
2,847.00
-
50
Cost of Goods Sold (COGS) incl. D&A
1,053.00
1,913.00
2,087.00
2,250.00
2,177.00
2,020
Gross Income
374.00
1,534.00
1,708.00
597.00
2,177.00
1,970
SG&A Expense
21,849.00
26,316.00
23,559.00
23,916.00
25,842.00
31,804
EBIT
22,223.00
27,850.00
25,267.00
23,319.00
28,019.00
33,774
Unusual Expense
140.00
83.00
664.00
30.00
481.00
1,114
Non Operating Income/Expense
691.00
755.00
149.00
39.00
331.00
8,548
Interest Expense
29.00
-
37.00
85.00
67.00
62
Pretax Income
21,155.00
26,932.00
24,677.00
23,246.00
27,814.00
26,126
Consolidated Net Income
21,155.00
26,932.00
24,677.00
23,246.00
27,814.00
26,126
Net Income
21,155.00
26,932.00
24,677.00
23,246.00
27,814.00
26,126
Net Income After Extraordinaries
21,155.00
26,932.00
24,677.00
23,246.00
27,814.00
26,126
Net Income Available to Common
21,155.00
26,932.00
24,677.00
23,246.00
27,814.00
26,126
EPS (Basic)
0.38
0.42
0.35
0.29
0.32
0.25
Basic Shares Outstanding
55,481.40
63,514.40
70,284.30
79,548.00
87,426.20
105,876.80
EPS (Diluted)
0.38
0.42
0.35
0.29
0.32
0.25
Diluted Shares Outstanding
55,481.40
63,514.40
70,284.30
79,548.00
87,426.20
105,876.80
EBITDA
21,190.00
25,948.00
23,193.00
21,169.00
25,842.00
31,756
Non-Operating Interest Income
266.00
246.00
112.00
149.00
122.00
276

About Pluristem Therapeutics

View Profile
Address
MATAM Advanced Technology Park
Haifa HA 31905
Israel
Employees -
Website http://www.pluristem.com
Updated 07/08/2019
Pluristem Therapeutics, Inc. is a biotechnology company, which engages in the provision of cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The company focuses on cell therapies for the treatment of diseases such as muscle injury, acute radiation syndrome, pulmonary arterial hypertension and others.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.